Genaissance Posts Q3 Revenue Rise | GenomeWeb

SAN FRANCISCO, Oct. 24 – Genaissance Pharmaceuticals on Wednesday posted third-quarter revenues of $1.1 million compared to $67,000 for the same quarter a year ago, the company announced.

“We have made considerable progress in the year since we completed our IPO,” Gualberto Ruano said in a statement. “Our technology is the gold standard for identifying gene variation, and our clinical development efforts have resulted in the initiation of the largest prospective genomics clinical trials ever conducted to correlate our proprietary gene markers with drug response.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."